Literature DB >> 11706121

Treatment of idiopathic restless legs syndrome (RLS) with gabapentin.

S Happe1, G Klösch, B Saletu, J Zeitlhofer.   

Abstract

Nine patients with idiopathic restless legs syndrome (RLS) were treated with 300 mg of gabapentin as an initial dose and an up-titration until relief of symptoms for 4 weeks. Subjective symptoms improved significantly. Polysomnographic data showed a reduction of periodic leg movements during sleep (PLMS) (p = 0.003) and PLMS index (p = 0.001). The authors conclude that gabapentin provides a well-tolerated and effective treatment of idiopathic RLS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706121     DOI: 10.1212/wnl.57.9.1717

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

Review 1.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

Review 3.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

5.  A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.

Authors:  Daniel O Lee; Ronald B Ziman; A Thomas Perkins; J Steven Poceta; Arthur S Walters; Ronald W Barrett
Journal:  J Clin Sleep Med       Date:  2011-06-15       Impact factor: 4.062

6.  A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Authors:  Clete A Kushida; Arthur S Walters; Philip Becker; Stephen G Thein; A Thomas Perkins; Thomas Roth; Daniel Canafax; Ronald W Barrett
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

7.  Treatment of sleep disorders in elderly patients.

Authors:  John J Harrington; Alon Y Avidan
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.598

Review 8.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

Review 9.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Gabapentin enacarbil - clinical efficacy in restless legs syndrome.

Authors:  Pinky Agarwal; Alida Griffith; Henry R Costantino; Narendra Vaish
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.